Effect of ulinastatin on clinical outcomes of patients with advanced lung cancer resection via thoracotomy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16008078

Enrollment

Unknown

Registered

2016-03-10

Start date

2015-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

U:continuously intravenously infusion ulinastatin

C:NS

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. aged 30-80 years; 2. clinical stage >=IIB; 3. ASA classification <=III; 4. elective thoracotomy lung cancer radical surgery.

Exclusion criteria

Exclusion criteria: 1. allergies to ulinastatin; 2. reoperation with recurrence tumor; 3. with other malignant tumor; 4. preoperative mechanical ventilation > 1h within two weeks; 5. BMI >=35 kg/m2; 6. acute respiratory failure(pneumonia, acute lung injury, ARDS).

Design outcomes

Primary

Measure	Time frame
postoperative pulmonary complications;hospital mortality;recurrence and metastasis rate;rate of survival;	—

Secondary

Measure	Time frame
postoperative extra-pulmonary complications;respiratory index;postoperative clinical recovery index;	—

Countries

China

Contacts

Public ContactLiu bin

West China Hospital, Sichuan University

liubin_hx@foxmail.com+86 18980601540

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026